scispace - formally typeset
R

Rama Shanker Verma

Researcher at Indian Institute of Technology Madras

Publications -  167
Citations -  3945

Rama Shanker Verma is an academic researcher from Indian Institute of Technology Madras. The author has contributed to research in topics: Stem cell & Mesenchymal stem cell. The author has an hindex of 30, co-authored 159 publications receiving 3160 citations. Previous affiliations of Rama Shanker Verma include University of Pennsylvania & Thapar University.

Papers
More filters
Journal ArticleDOI

Nanosecond laser ablation enhances cellular infiltration in a hybrid tissue scaffold.

TL;DR: The findings suggest the feasibility to selectively ablate polymer layer in the HTE scaffolds without affecting their bio-mechanical properties and also describe a new approach to enhance cellular infiltration on the Bio-Hybrid scaffolds.
Journal ArticleDOI

High cholesterol diet increases MMP9 and CD40 immunopositivity in early atherosclerotic plaque in rabbits.

TL;DR: It is concluded that a high cholesterol diet up-regulates CD68 and CD40, which may play a possible role in the remodelling and destabilization of the atherosclerotic plaque of arteries with the up-regulation of MMP9 and hsCRP.
Journal ArticleDOI

Cardiac Differentiation of Mesenchymal Stem Cells: Impact of Biological and Chemical Inducers.

TL;DR: In this paper, a review highlights the impact and recent trends in employing biological and chemical inducers on cardiac differentiation of mesenchymal Stem Cells (MSCs) and provides an insight on skeptical roles of cell free biological factors and extracellular scaffold assisted mode for manipulation of native and transplanted stem cells towards translational cardiac research.
Journal ArticleDOI

Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy.

TL;DR: In this paper, the authors designed a multifunctional drug delivery platform for concurrent delivery of either PAC or PARP inhibitor (olaparib) and FOXM1 siRNA in chitosan-coated poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles with the ability to emerge as a front runner therapeutic for TNBC therapy.
Journal ArticleDOI

Insilco analysis of functionally important residues in folate receptors

TL;DR: With sequence alignment and PROSITE motif identification, this work attempted to answer evolutionarily significant residues that are of functional importance for ligand binding and that form catalytic sites of folate binding proteins.